Strides Pharma Science Limited will conduct a series of Non-Deal Road Show meetings with analysts and institutional investors across the United States from June 2 to June 5, 2026. These engagements aim to discuss the company's financial performance for the quarter ended March 31, 2026, utilizing the Q4FY26 earnings presentation uploaded to the stock exchanges and company website on May 18, 2026. The meetings provide a platform for investors to review quarterly results and the business outlook directly with the management.

The schedule includes in-person one-on-one sessions in four major cities. The first meeting is scheduled in New York on June 2, followed by Chicago on June 3, Salt Lake City on June 4, and concluding in Los Angeles on June 5.

Manjula Ramamurthy, Company Secretary & Compliance Officer, signed the disclosure on May 28, 2026.

Strides Pharma Science Limited has confirmed that its promoters and promoter group did not encumber any shares during the financial year ended March 31, 2026. The disclosure, submitted to the stock exchanges, assures investors that no new pledges or charges were created on the promoter holdings, other than those already reported.

The declaration was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires listed companies to inform the exchanges if promoters have pledged their shares as collateral, a move that can signal financial stress or risk for shareholders.

Pronomz Ventures LLP, representing the promoters and promoter group, communicated the status to the National Stock Exchange of India Limited and BSE Limited. The firm confirmed that the shareholding remained free from fresh encumbrances throughout FY26.

The filing was signed by Chandrappa Seetharamaiah, Designated Partner of Pronomz Ventures LLP. The document was submitted to the exchanges on April 7, 2026, for their information and records.